Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Connecticut
Clinical trial register · United States · industry-sponsored

Clinical Trials in Connecticut, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269

Trials with a site in Connecticut

1301 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
235
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Virginia
2024-12-16
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-12-16
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
Connecticut, Florida, Georgia, Mississippi, New Jersey, New York, Ohio, Pennsylvania
2024-12-16
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-12-13
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-12-12
Recruiting
BeOne Medicines
Phase 1
168
California, Connecticut, Minnesota, Texas, Washington, Wisconsin
2024-12-09
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
160
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2024-12-06
Recruiting
Beam Therapeutics Inc.
Phase 1/2
36
California, Connecticut, Texas
2024-12-06
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New Jersey, New York
2024-12-06
Recruiting
OSE Immunotherapeutics
Phase 3
363
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana
2024-12-03
Active, closed
H. Lundbeck A/S
Phase 3
401
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Indiana, Maryland
2024-12-03
Active, closed
ViiV Healthcare
Phase 3
326
Alabama, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2024-12-02
Active, closed
Ocular Therapeutix, Inc.
Phase 3
825
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-11-27
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2024-11-27
Active, closed
CereVasc Inc
Not applicable
230
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Massachusetts
2024-11-26
Recruiting
Adcendo ApS
Phase 1
210
Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas
2024-11-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Connecticut, Michigan, Missouri, New York, Texas, Virginia, Washington
2024-11-25
Recruiting
External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
NCT06788977Pregnancy, Migraine, Headache, Postpartum
Cefaly Technology
Observational
550
Connecticut
2024-11-25
Active, closed
Regeneron Pharmaceuticals
Observational
368
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-11-22
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
570
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Mississippi, New York
2024-11-21
Recruiting
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
NCT06458712Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Duke Street Bio Ltd
Phase 1
180
California, Connecticut, New York, Texas
2024-11-21
Active, closed
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
TORL Biotherapeutics, LLC
Phase 2
230
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2024-11-20
Active, closed
Avalus Ultra Post-Approval Study (PAS)
NCT06506903Aortic Valve Disease
Medtronic Cardiac Surgery
Not applicable
190
Connecticut, Florida, Georgia, Illinois, Michigan, Minnesota, New York, Ohio
2024-11-20
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Puma Biotechnology, Inc.
Phase 2
225
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-11-19
Active, closed
Daiichi Sankyo
Phase 3
700
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2024-11-19
Recruiting
Eli Lilly and Company
Phase 3
150
California, Connecticut, Georgia, Illinois, Louisiana, Missouri, North Carolina, Pennsylvania
2024-11-18
Recruiting
Ensoma
Observational
60
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-11-18
Recruiting
Day One Biopharmaceuticals, Inc.
Phase 1
300
Connecticut, Florida, Indiana, Michigan, New York, Oklahoma, Tennessee, Texas
2024-11-18
Recruiting
AstraZeneca
Phase 3
1,160
Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Idaho
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
125
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-18
By invitation
Integra LifeSciences Corporation
Not applicable
350
California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland, New York
2024-11-18
Recruiting
Genentech, Inc.
Phase 1
410
California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Michigan, New York
2024-11-14
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Iowa
2024-11-12
Active, closed
AbbVie
Phase 2
74
California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-11-08
Recruiting
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
NCT06636383Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical Inc
Observational
140
California, Colorado, Connecticut, Michigan, North Carolina, Ohio, Pennsylvania, Texas
2024-11-04
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2024-11-01
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Connecticut, Ohio, Oklahoma, Texas, Virginia
2024-10-30
Recruiting
Regeneron Pharmaceuticals
Phase 3
975
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-10-30
Active, closed
BioPorto Diagnostics
Observational
800
Alabama, California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New Mexico
2024-10-28
Recruiting
Stemline Therapeutics, Inc.
Phase 1
240
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2024-10-25
Active, closed
Eli Lilly and Company
Phase 3
1,400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-10-24
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2024-10-22
Active, closed
Abcuro, Inc.
Phase 2/3
270
Arizona, California, Connecticut, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2024-10-21
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2024-10-21
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-18
Recruiting
argenx
Phase 3
69
Arizona, California, Colorado, Connecticut, District of Columbia, Illinois, Iowa, Louisiana
2024-10-18
Active, closed
Uniquity One (UNI)
Phase 2
184
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2024-10-16
Active, closed
Ipsen
Observational
424
California, Colorado, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina
2024-10-14
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2024-10-14
Active, closed
SK Life Science, Inc.
Phase 4
49
Arizona, Arkansas, California, Connecticut, Florida, Idaho, Kentucky, Louisiana
2024-10-14
Recruiting
Boehringer Ingelheim
Phase 2
588
Alaska, Arizona, California, Connecticut, Florida, Illinois, Indiana, Maryland
2024-10-11
Active, closed
Incyte Corporation
Phase 2
130
Arizona, California, Colorado, Connecticut, Florida, Illinois, Maryland, Missouri
2024-10-11
Active, closed
Eli Lilly and Company
Phase 2
143
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2024-10-10
Active, closed
Ipsen
Phase 2
670
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Louisiana
2024-10-10
Active, closed
Gilead Sciences
Phase 3
609
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-09
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1/2
39
California, Connecticut, Indiana, Minnesota, Tennessee
2024-10-09
Active, closed
Vaxart
Phase 2
5,485
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-08
Active, closed
Gilead Sciences
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-08
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Akero Therapeutics, Inc
Phase 3
2,150
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-04
Recruiting
SoniVie Inc.
Not applicable
261
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Louisiana
2024-10-03
Recruiting
BeOne Medicines
Phase 1
310
Arizona, California, Colorado, Connecticut, Illinois, Kansas, Mississippi, New Jersey
2024-10-03
Recruiting
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT06561048Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Corvus Pharmaceuticals, Inc.
Phase 3
150
California, Connecticut, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts
2024-10-02
Recruiting
Ferring Pharmaceuticals
Phase 3
250
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-01
Active, closed
SIMPLAAFY Clinical Trial
NCT06521463Atrial Fibrillation, Stroke, Bleeding
Boston Scientific Corporation
Not applicable
1,857
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-01
Recruiting
GlaxoSmithKline
Phase 1
845
California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina
2024-09-30
Active, closed
Eisai Inc.
Phase 2
105
Arizona, Connecticut, Florida, Georgia, Mississippi, Missouri, Pennsylvania, Tennessee
2024-09-30
Active, closed
Stemline Therapeutics, Inc.
Phase 3
4,556
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-09-27
Recruiting
Registry for Stage 2 Type 1 Diabetes
NCT06481904Type 1 Diabetes
DrugTzield
Sanofi
Observational
200
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-09-27
Active, closed
BioCryst Pharmaceuticals
Phase 1
76
California, Connecticut, Illinois, Indiana
2024-09-26
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Mississippi
2024-09-26
Active, closed
A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System
NCT06564636Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis
Smith & Nephew, Inc.
Observational
119
California, Connecticut, Florida, Illinois, New York, North Carolina
2024-09-26
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-09-26
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
240
California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas
2024-09-23
Active, closed
Hoffmann-La Roche
Phase 3
338
Arizona, California, Connecticut, Florida, Illinois, Maine, Massachusetts, Michigan
2024-09-23
Recruiting
Autobahn Therapeutics, Inc.
Phase 2
230
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts
2024-09-20
Active, closed
Cerevance
Phase 3
330
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas
2024-09-20
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2024-09-18
Active, closed
Amgen
Phase 1
49
California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma
2024-09-17
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
190
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland
2024-09-17
Active, closed
Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery
NCT06642051Chronic Venous Insufficiency, CVI, Venous Malformations, Venous Leg Ulcers, Klippel-Trenaunay Syndrome
Sonablate
Not applicable
30
Connecticut
2024-09-11
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
130
Arizona, California, Colorado, Connecticut, Florida, Indiana, Louisiana, Michigan
2024-09-11
Active, closed
AbbVie
Phase 3
496
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii
2024-09-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
560
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-09-09
Recruiting
RevCore for In Stent Thrombosis
NCT06394739In-stent Thrombosis
Inari Medical
Observational
100
Connecticut, District of Columbia, Idaho, Maryland, New York, North Carolina, Ohio, Pennsylvania
2024-09-09
Recruiting
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.
Phase 1
329
Connecticut, Florida, Michigan, New Jersey, New York, Ohio, Tennessee, Texas
2024-09-05
Recruiting
AbbVie
Phase 2
590
Alabama, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2024-09-04
Recruiting
Kardion Inc
Not applicable
310
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Indiana, Massachusetts
2024-09-03
Not yet open
Abbott Nutrition
Not applicable
321
Arizona, Arkansas, Connecticut, Florida, Massachusetts, Missouri, New Mexico, New York
2024-09
Active, closed
LMN-201 for Prevention of C. Difficile Infection Recurrence
NCT05330182Clostridioides Difficile Infection
Lumen Bioscience, Inc.
Phase 2/3
375
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota, New York
2024-08-29
Active, closed
Gilead Sciences
Phase 3
640
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-28
Recruiting
Prevail Therapeutics
Phase 1
124
Colorado, Connecticut, Florida, Illinois, Michigan, Pennsylvania, Texas
2024-08-27
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
BioNTech SE
Phase 2
83
California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee
2024-08-26
Recruiting
Janssen Research & Development, LLC
Phase 2
210
California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington
2024-08-26
Active, closed
Kodiak Sciences Inc
Phase 3
667
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-23
Active, closed
Skye Bioscience, Inc.
Phase 2
136
Alabama, California, Connecticut, Georgia, Kentucky, Nebraska, Nevada, New Hampshire
2024-08-22
Recruiting
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas
2024-08-21
Recruiting
Noveome Biotherapeutics, formerly Stemnion
Phase 1/2
36
Arkansas, Connecticut, Florida, Illinois, Oklahoma, Pennsylvania
2024-08-19
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2024-08-16
Active, closed
AbbVie
Phase 3
111
California, Colorado, Connecticut, Illinois, Indiana, Massachusetts, Minnesota, New York
2024-08-08
Recruiting
BioMarin Pharmaceutical
Observational
300
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-08-08
Active, closed
EyeBiotech Ltd.
Phase 2/3
984
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Iowa
2024-08-07
Recruiting
AstraZeneca
Phase 3
1,018
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2024-08-07
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-07-30
Recruiting
Janssen Research & Development, LLC
Phase 3
752
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-07-25
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland
2024-07-24
Active, closed
OncoVerity, Inc.
Phase 2
140
Arizona, California, Colorado, Connecticut, Florida, Iowa, Kentucky, New Jersey
2024-07-22
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Arizona, California, Connecticut, Florida, Illinois, Michigan, Mississippi, New Jersey
2024-07-22
Recruiting
TG Therapeutics, Inc.
Observational
2,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-07-22
Recruiting
Amgen
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Michigan
2024-07-17
Recruiting
Bristol-Myers Squibb
Phase 1/2
224
Alabama, California, Connecticut, Georgia, Illinois, Kansas, Maryland, Massachusetts
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Arizona, California, Colorado, Connecticut, Indiana, Michigan, Nevada, North Carolina
2024-07-16
Recruiting
AstraZeneca
Phase 2
80
California, Connecticut, Florida, Iowa, Kentucky, Maryland, Michigan, South Dakota
2024-07-16
Active, closed
Zydus Therapeutics Inc.
Phase 3
102
California, Colorado, Connecticut, Florida, Georgia, Indiana, New York, North Carolina
2024-07-16
Active, closed
Genentech, Inc.
Phase 2
30
Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Kentucky, Louisiana
2024-07-15
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
109
Alabama, California, Colorado, Connecticut, Florida, Illinois, Kansas, Louisiana
2024-07-12
Recruiting
Philogen S.p.A.
Phase 2
162
Connecticut, New York
2024-07-12
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC
Phase 3
156
California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa, Maryland
2024-07-09
Recruiting
Cabaletta Bio
Phase 2/3
37
Connecticut, Florida, Illinois, Kansas, Michigan, Minnesota, New York, North Carolina
2024-07-02
Active, closed
AstraZeneca
Phase 3
339
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-06-29
Active, closed
Biosense Webster, Inc.
Not applicable
354
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2024-06-28
Recruiting
Boehringer Ingelheim
Phase 1/2
910
California, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts, Michigan
2024-06-28
Recruiting
Global Paradise System US Post Approval Study
NCT06297291Hypertension, Cardiovascular Diseases, Vascular Diseases
ReCor Medical, Inc.
Observational
1,000
California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Kansas
2024-06-28
Recruiting
Intensity Therapeutics, Inc.
Phase 3
333
Arizona, California, Connecticut, Florida, Michigan, Minnesota, Nebraska, North Carolina
2024-06-28
Active, closed
AbbVie
Phase 3
1,400
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-27
Recruiting
Tempus AI
Observational
500
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-06-26
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2024-06-25
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Arizona, Colorado, Connecticut, District of Columbia, Florida, Kansas, North Carolina, Ohio
2024-06-25
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-06-24
Recruiting
Medtronic - MITG
Not applicable
278
Connecticut, Illinois, Massachusetts, New Jersey, New York
2024-06-21
Active, closed
Sanofi
Phase 2
185
Alabama, Arizona, California, Colorado, Connecticut, Florida, Indiana, Massachusetts
2024-06-20
Recruiting
Schrödinger, Inc.
Phase 1
52
Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee
2024-06-18
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-06-17
By invitation
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
NCT06363760Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Editas Medicine, Inc.
Observational
54
California, Colorado, Connecticut, Florida, Georgia, Minnesota, New York, North Carolina
2024-06-17
Active, closed
AbbVie
Phase 3
184
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-14
Recruiting
Kuros Biosurgery AG
Not applicable
100
Connecticut, Illinois, Maryland, Michigan, North Carolina, Ohio, Utah, Virginia
2024-06-10
Recruiting
Immunocore Ltd
Phase 3
680
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-06-05
Active, closed
Amgen
Phase 3
563
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2024-06-05
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Colorado, Connecticut, Florida, Kentucky, Missouri, Nevada, New Mexico, Oklahoma
2024-06-04
Active, closed
Stealth BioTherapeutics Inc.
Phase 3
313
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2024-05-30
Active, closed
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
NCT06106672Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
54
Arizona, California, Connecticut, Florida, Illinois, Kansas, Michigan, Missouri
2024-05-30
Active, closed
ShiraTronics
Not applicable
250
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-05-29
Active, closed
Amgen
Phase 1
120
California, Colorado, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Missouri
2024-05-29
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
California, Connecticut, Florida, Illinois, Missouri, Montana, New Jersey, New York
2024-05-24
Recruiting
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
Revolution Medicines, Inc.
Phase 1/2
1,130
Arizona, California, Colorado, Connecticut, Florida, Kansas, Maryland, Massachusetts
2024-05-24
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan
2024-05-22
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2024-05-20
Active, closed
Alnylam Pharmaceuticals
Phase 2
210
California, Colorado, Connecticut, Florida, Illinois, Kentucky, Louisiana, Massachusetts
2024-05-17
Recruiting
Boehringer Ingelheim
Phase 2
175
Arizona, California, Colorado, Connecticut, Florida, Hawaii, Maine, Maryland
2024-05-15
Recruiting
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
NCT06116110Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma
Miltenyi Biomedicine GmbH
Observational
150
Arizona, California, Connecticut, Illinois, Kansas, Maryland, Massachusetts, North Carolina
2024-05-15
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
858 Therapeutics, Inc.
Phase 1/2
120
Arizona, Connecticut, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio
2024-05-13
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Kentucky, Louisiana
2024-05-13
Active, closed
Sanofi
Phase 3
1,541
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2024-05-08
Active, closed
TScan Therapeutics, Inc.
Phase 1
840
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2024-05-06
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Colorado, Connecticut, Florida, Nevada, Ohio, Texas
2024-05-01
By invitation
Travere Therapeutics, Inc.
Phase 3
100
Arizona, Connecticut, Georgia, Illinois, Maine, Maryland, New York, North Carolina
2024-04-30
Active, closed
Eli Lilly and Company
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-04-30
Recruiting
HiberCell, Inc.
Phase 1
80
Arizona, California, Colorado, Connecticut, Michigan, Minnesota, Missouri, New York
2024-04-29
Recruiting
AstraZeneca
Phase 3
582
California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maryland
2024-04-29
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2024-04-29
Recruiting
CSL Behring
Phase 2/3
3,110
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-04-27
Active, closed
AbbVie
Phase 2/3
2,701
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2024-04-26
Recruiting
Axsome Therapeutics, Inc.
Phase 3
450
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2024-04-26
Recruiting
Janssen Research & Development, LLC
Phase 1/2
287
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Missouri
2024-04-22
Active, closed
Takeda
Phase 4
50
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2024-04-18
Recruiting
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
NCT05908331In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
Concept Medical Inc.
Not applicable
492
Alabama, Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Minnesota
2024-04-16
Recruiting
Medtronic Neurovascular Clinical Affairs
Not applicable
300
California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts
2024-04-16
Active, closed
Merck Sharp & Dohme LLC
Phase 2
272
California, Connecticut, Massachusetts, New York, North Carolina, Pennsylvania, Texas
2024-04-10
Recruiting
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation
Nested Therapeutics, Inc
Phase 1
230
California, Colorado, Connecticut, Florida, New York, Pennsylvania, Tennessee, Texas
2024-04-09
Active, closed
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Ipsen
Phase 1/2
36
California, Connecticut, Tennessee, Virginia
2024-04-03
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
Avalyn Pharma Inc.
Phase 2
398
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-04-03
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
43
Connecticut, Maryland, Minnesota, Missouri, North Carolina, Tennessee
2024-04-02
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Alabama, California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Nebraska
2024-04-01
Active, closed
AstraZeneca
Phase 3
2,554
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-03-29
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Alabama, California, Colorado, Connecticut, Kansas, Massachusetts, Missouri, New Jersey
2024-03-28
Active, closed
Gilead Sciences
Phase 3
577
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2024-03-25
Recruiting
GlaxoSmithKline
Phase 3
864
Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Iowa
2024-03-21
Active, closed
Bristol-Myers Squibb
Phase 2
310
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, New Hampshire
2024-03-20
Active, closed
GlaxoSmithKline
Phase 4
177
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana, Maryland
2024-03-20
Recruiting
Translational Sciences, Inc.
Phase 2
300
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2024-03-18
Recruiting
Verastem, Inc.
Phase 3
270
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2024-03-18
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2024-03-14
Recruiting
Janssen Research & Development, LLC
Phase 3
120
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Recruiting
Eli Lilly and Company
Phase 3
90
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Active, closed
AbbVie
Phase 1
152
California, Connecticut, Florida, Illinois, Michigan, North Carolina, Rhode Island, Texas
2024-03-08
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Active, closed
Eli Lilly and Company
Phase 3
17,300
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-03-05
Active, closed
Acumen Pharmaceuticals
Phase 2
542
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Mississippi
2024-02-29
Recruiting
Daiichi Sankyo
Phase 2/3
860
Alaska, Connecticut, Florida, Indiana, Kentucky, Massachusetts, Missouri, New Jersey
2024-02-27
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
Daiichi Sankyo
Phase 2
890
California, Connecticut, Florida, Illinois, Maryland, Minnesota, Missouri, New York
2024-02-26
Active, closed
Dianthus Therapeutics
Phase 2
65
Arizona, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Massachusetts
2024-02-23
Recruiting
ParVation Therapeutics, Inc.
Phase 1
400
Connecticut, Pennsylvania, Tennessee, Texas, Utah
2024-02-23
Recruiting
Kura Oncology, Inc.
Phase 1
171
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Iowa, Kansas
2024-02-22
Recruiting
Pulmonx Corporation
Not applicable
200
Arizona, Colorado, Connecticut, Florida, Illinois, Kentucky, Massachusetts, Michigan
2024-02-22
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Amgen
Phase 3
404
California, Connecticut, Florida, Kentucky, Louisiana, New Jersey, New York, North Carolina
2024-02-20
Recruiting
Microvention-Terumo, Inc.
Observational
750
California, Colorado, Connecticut, Florida, Hawaii, Iowa, Kentucky, Michigan
2024-02-19
Active, closed
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Recruiting
Cabaletta Bio
Phase 1/2
28
California, Connecticut, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2024-02-16
Recruiting
OnCusp Therapeutics, Inc.
Phase 1
263
Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee
2024-02-09
By invitation
Sarepta Therapeutics, Inc.
Observational
500
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Illinois
2024-02-07
Recruiting
Akeso
Phase 2
90
California, Colorado, Connecticut, Florida, Maryland, Missouri, New York, North Carolina
2024-02-07
Recruiting
Quanta Therapeutics
Phase 1
250
California, Colorado, Connecticut, Florida, New York, North Carolina, Oklahoma, Tennessee
2024-02-05
Recruiting
Cumberland Pharmaceuticals
Phase 2
128
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Michigan
2024-01-31
Active, closed
Ocular Therapeutix, Inc.
Phase 3
344
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-01-29
Recruiting
Accuro XV Ultrasound Imaging System for BoneEnhance and Fracture Detection Algorithms
NCT07853768Fracture Arm, Fracture Leg, Wrist Injury, Ankle Injury
Rivanna Medical, Inc.
Not applicable
25,000
California, Colorado, Connecticut, Illinois, Pennsylvania, Texas, Utah, Virginia
2024-01-29
Active, closed
Registry of the Patient Experience for Carpal Tunnel Release
NCT06071468Carpal Tunnel Syndrome, CTS
Sonex Health, Inc.
Observational
1,424
Alabama, Arizona, Connecticut, Florida, Indiana, Massachusetts, Michigan, Minnesota
2024-01-26
Recruiting
STIMIT Activator 1 IDE Study
NCT05883163Diaphragm Issues
Stimit AG
Not applicable
40
Connecticut, Massachusetts, Virginia
2024-01-24
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, California, Colorado, Connecticut, Florida, Massachusetts, New York, Tennessee
2024-01-23
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
California, Connecticut, Florida, Michigan, New Jersey, New York, North Carolina, Ohio
2024-01-23
Recruiting
AstraZeneca
Phase 1/2
334
California, Connecticut, Maryland, Oregon, Pennsylvania, Rhode Island, Virginia
2024-01-18
Active, closed
Regeneron Pharmaceuticals
Observational
11
Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana, Michigan, Ohio
2024-01-17
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 3
410
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-01-11
Recruiting
Fate Therapeutics
Phase 1
351
Arizona, California, Connecticut, Illinois, Michigan, Minnesota, Missouri, New York
2024-01-05
Active, closed
CONMED Corporation
Not applicable
268
Connecticut
2024-01-05
Active, closed
HistoSonics, Inc.
Not applicable
67
California, Connecticut, Florida, Maryland, Massachusetts, New York, Ohio, Texas
2024-01-04
By invitation
Wren Laboratories LLC
Observational
400
Connecticut
2024-01-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Louisiana
2023-12-31
Recruiting
Travere Therapeutics, Inc.
Phase 3
70
Arizona, Connecticut, Georgia, Illinois, Maine, Maryland, New York, North Carolina
2023-12-28
Active, closed
Sanofi
Phase 3
943
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-27
Recruiting
Caregen Co. Ltd.
Phase 1
45
Connecticut, Florida, Georgia, Indiana, North Dakota, Pennsylvania
2023-12-22
Recruiting
IO Biotech
Phase 2
60
Connecticut, Massachusetts, Virginia
2023-12-21
Recruiting
Eli Lilly and Company
Phase 3
1,264
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-18
Active, closed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
CG Oncology, Inc.
Phase 3
367
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-14
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
54
California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, New York, Ohio
2023-12-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Indiana
2023-12-13
Active, closed
Sanofi
Phase 3
1,655
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-13
Recruiting
Intellia Therapeutics
Phase 3
1,200
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-13
Recruiting
Eikon Therapeutics
Phase 1/2
156
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Michigan, Minnesota
2023-12-11
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Connecticut, Florida, Georgia, Minnesota, Nebraska, New York, Oregon, South Carolina
2023-12-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2023-12-06
Active, closed
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153Neovascular Age-related Macular Degeneration (nAMD)
Alcon Research
Phase 1/2
139
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-12-06
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
BriaCell Therapeutics Corporation
Phase 3
404
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2023-12-05
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-01
Active, closed
argenx
Observational
413
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-29
By invitation
Evaluation of the GORE® Ascending Stent Graft
NCT05800743Aortic Aneurysm, Thoracic, Pseudoaneurysm, Aortic Dissection, Aorta; Lesion
W.L.Gore & Associates
Not applicable
370
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-11-28
Recruiting
Freenome Holdings Inc.
Observational
20,000
California, Connecticut, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-11-28
Active, closed
Genentech, Inc.
Phase 1
65
Alabama, Connecticut, New York, Ohio, Pennsylvania, Tennessee
2023-11-27
By invitation
CRISPR Therapeutics AG
Observational
70
California, Connecticut, Georgia, Illinois, Kansas, Minnesota, Missouri, New York
2023-11-22
Active, closed
AstraZeneca
Phase 3
1,898
Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois, Indiana
2023-11-21
Active, closed
SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
NCT06120205Hpv, HPV 16 Infection, HPV Infection, High Risk HPV
Teal Health, Inc.
Not applicable
870
Alabama, California, Colorado, Connecticut, Louisiana, Maryland, Massachusetts, Missouri
2023-11-20
Recruiting
Eli Lilly and Company
Phase 2
1,481
Arizona, California, Connecticut, Florida, Hawaii, Idaho, Illinois, Iowa
2023-11-17
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Oncology, Inc.
Phase 3
510
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2023-11-16
Active, closed
AbbVie
Phase 3
289
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2023-11-15
Active, closed
AstraZeneca
Phase 3
1,902
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-11-14
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2023-11-14
Active, closed
AstraZeneca
Phase 3
314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-08
Recruiting
Qualigen Theraputics, Inc.
Phase 1
54
Arizona, Connecticut, Michigan, Texas
2023-11-01
Recruiting
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211Single Ventricle Heart Disease
Mezzion Pharma Co. Ltd
Phase 3
436
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-10-30
Active, closed
Summit Therapeutics
Phase 3
1,600
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-10-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
402
California, Connecticut, Florida, Hawaii, Illinois, Indiana, Louisiana, Maryland
2023-10-24
Recruiting
Hoffmann-La Roche
Phase 3
182
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Michigan, Missouri
2023-10-22
Active, closed
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
960
Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii
2023-10-20
Recruiting
Regeneron Pharmaceuticals
Observational
20
California, Connecticut, Illinois, Maryland, Minnesota, New York, Pennsylvania
2023-10-19
Active, closed
Genentech, Inc.
Phase 2
260
California, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Michigan, Nebraska
2023-10-18
Recruiting
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
Volastra Therapeutics, Inc.
Phase 1/2
200
California, Colorado, Connecticut, Illinois, Indiana, Maryland, Michigan, New York
2023-10-18
Active, closed
Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
NCT05295628Aortic Valve Stenosis, Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Valve Replacement
Emblok, Inc.
Not applicable
532
Arizona, California, Connecticut, District of Columbia, Illinois, Iowa, Kansas, Louisiana
2023-10-17
Active, closed
Ipsen
Phase 3
759
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-10-12
Active, closed
Gilead Sciences
Phase 1
45
Connecticut, Tennessee, Texas
2023-10-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-10-09
By invitation
The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)
NCT06315023Peripheral Arterial Disease, Symptomatic Femoropopliteal Lesions
Endologix
Observational
450
California, Connecticut, District of Columbia, Florida, Massachusetts, Missouri, New York, Ohio
2023-10-06
Active, closed
AstraZeneca
Phase 3
5,511
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2023-10-05
Active, closed
Bristol-Myers Squibb
Phase 3
106
California, Connecticut, Florida, Kansas, Kentucky, Michigan, Missouri, New Jersey
2023-10-05
Recruiting
DalCor Pharmaceuticals
Phase 3
2,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-10-03
Active, closed
Ipsen
Phase 3
751
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Maryland
2023-09-29
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
92
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Michigan
2023-09-22
Recruiting
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
Active, closed
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
NCT05907564Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases
Inquis Medical, Inc.
Not applicable
120
Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Louisiana
2023-09-20
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Alaska, California, Colorado, Connecticut, District of Columbia, Florida, Hawaii, Illinois
2023-09-18
Active, closed
Hoffmann-La Roche
Phase 3
687
Arkansas, California, Connecticut, District of Columbia, Florida, Illinois, Kentucky, Louisiana
2023-09-14
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-09-14
By invitation
argenx
Phase 3
240
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, New York
2023-09-12
Active, closed
Q32 Bio Inc.
Phase 2
75
Arizona, Arkansas, California, Connecticut, Florida, Indiana, Kentucky, Massachusetts
2023-09-12
Recruiting
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Revolution Medicines, Inc.
Phase 1
604
California, Connecticut, Florida, Maryland, Massachusetts, New York, North Carolina, Ohio
2023-09-07
Active, closed
Humacyte, Inc.
Phase 3
121
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Maryland
2023-09-07
Recruiting
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Phanes Therapeutics
Phase 1/2
203
California, Colorado, Connecticut, Maryland, Massachusetts, Missouri, North Carolina, Oklahoma
2023-09-05
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Kentucky, Maryland
2023-09-01
Active, closed
Cytokinetics
Phase 3
500
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2023-08-31
Recruiting
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT05798923Pulmonary Hypertension Due to Lung Diseases and Hypoxia
IRulya Therapeutics Inc.
Phase 2
85
Arizona, Connecticut, Massachusetts, Pennsylvania
2023-08-30
Recruiting
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT05867251Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
Avenzo Therapeutics, Inc.
Phase 1/2
430
Connecticut, Florida, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas
2023-08-30
Recruiting
Pliant Therapeutics, Inc.
Phase 1
124
Connecticut, District of Columbia, Georgia, Michigan, Missouri, New Jersey, New York, North Carolina
2023-08-30
Recruiting
TransMedics
Observational
100,000
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2023-08-25
Active, closed
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
NCT05929235Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
Flare Therapeutics Inc.
Phase 1
120
California, Connecticut, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio
2023-08-24
Active, closed
Erasca, Inc.
Phase 1
86
California, Connecticut, Florida, Georgia, Michigan, Missouri, Nevada, Oregon
2023-08-17
Active, closed
ViiV Healthcare
Phase 2
185
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2023-08-17
Active, closed
Emalex Biosciences Inc.
Phase 3
150
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-08-16
Recruiting
Novartis Pharmaceuticals
Phase 4
700
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2023-08-14
Recruiting
Novian Health Inc.
Not applicable
122
California, Connecticut, Maryland, New Jersey, New York
2023-08-09
Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
SystImmune Inc.
Phase 1
540
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa, Kentucky
2023-08-08
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
160
Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Mississippi
2023-08-08
Recruiting
GlaxoSmithKline
Phase 3
892
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-08-01
Recruiting
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
NCT05762107Type 1 Diabetes Mellitus With Hypoglycemia
Zucara Therapeutics Inc.
Phase 2
186
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-28
Active, closed
AbbVie
Phase 3
1,014
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-25
Active, closed
Hoffmann-La Roche
Phase 2
21
Alabama, Connecticut, Florida, Massachusetts, Michigan
2023-07-24
Recruiting
Carevive Systems, Inc.
Observational
25
Connecticut, Illinois, North Carolina, Ohio
2023-07-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Arkansas, California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts
2023-07-19
Recruiting
Kura Oncology, Inc.
Phase 1
420
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2023-07-18
Recruiting
Caption Health, Inc.
Not applicable
220
Connecticut, Illinois, North Carolina
2023-07-17
Recruiting
BioAtla, Inc.
Phase 1
168
California, Connecticut, Illinois, Michigan, Ohio, Washington
2023-07-14
Active, closed
Mineralys Therapeutics Inc.
Phase 3
1,076
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2023-07-14
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-11
Active, closed
Novo Nordisk A/S
Phase 3
212
California, Connecticut, Georgia, Idaho, Louisiana, Maryland, Massachusetts, Minnesota
2023-07-07
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
149
Arizona, California, Connecticut, Florida, Illinois, Louisiana, Mississippi, Missouri
2023-06-30
Recruiting
DynamiCure Biotechnology
Phase 1
320
Alabama, Arizona, Colorado, Connecticut, Florida, Maryland, Massachusetts, Minnesota
2023-06-28
Active, closed
Cognition Therapeutics
Phase 2
540
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Indiana
2023-06-28
Active, closed
OncoC4, Inc.
Phase 3
630
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Kansas
2023-06-28
Active, closed
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
TScan Therapeutics, Inc.
Observational
1,150
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2023-06-26
Active, closed
AbbVie
Phase 3
1,328
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2023-06-21
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 3
69
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois
2023-06-14
Recruiting
H. Lundbeck A/S
Phase 3
315
Connecticut, Florida, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina
2023-06-08
Recruiting
Study of ALTO-300 in MDD
NCT05922878Major Depressive Disorder
Alto Neuroscience
Phase 2
325
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2023-06-08
Active, closed
Bristol-Myers Squibb
Phase 1/2
100
California, Connecticut, New Jersey, New York
2023-06-06
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
Nuvation Bio Inc.
Phase 3
365
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-06-05
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Indiana
2023-06-01
Recruiting
ZetrOZ, Inc.
Phase 1
90
Connecticut, Virginia
2023-06-01
Recruiting
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
NCT05972070Myocardial Infarction, Percutaneous Transluminal Coronary Angioplasty, Coronary Artery Bypass, Stable Angina
ROM Technologies, INC
Observational
500
Connecticut
2023-06-01
Active, closed
MapLight Therapeutics
Phase 2
120
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri
2023-06-01
Recruiting
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
Parabilis Medicines, Inc.
Phase 1/2
619
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Maryland, Massachusetts
2023-05-23
Active, closed
MeiraGTx, LLC
Phase 1/2
13
Connecticut, Michigan, New York, Pennsylvania, West Virginia
2023-05-19
Active, closed
Assessment of Combined CCM and ICD Device in HFrEF
NCT05855135Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy
Impulse Dynamics
Not applicable
300
Arizona, California, Connecticut, Florida, Iowa, Kansas, Kentucky, Massachusetts
2023-05-17
Active, closed
Gilead Sciences
Phase 2
83
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Missouri, New Mexico
2023-05-15
Recruiting
XTX301 in Patients With Advanced Solid Tumors
NCT05684965Advanced Solid Tumor
Xilio Development, Inc.
Phase 1/2
358
California, Connecticut, Minnesota, Missouri, New Jersey, Ohio, Pennsylvania, Texas
2023-05-11
Active, closed
Gilead Sciences
Phase 3
654
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas, Louisiana
2023-05-08
Active, closed
Shockwave Medical, Inc.
Observational
399
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas, Louisiana
2023-05-03
Active, closed
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Regeneron Pharmaceuticals
Phase 2
22
Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas, Massachusetts
2023-05-03
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
470
Alabama, California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2023-05-02
Recruiting
Genentech, Inc.
Phase 1
210
Arizona, Connecticut, Florida, Illinois, Texas
2023-05-02
Recruiting
Varian, a Siemens Healthineers Company
Not applicable
380
California, Connecticut, Massachusetts, Minnesota, Missouri, Ohio, Pennsylvania, South Carolina
2023-04-21
Active, closed
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
IDEAYA Biosciences
Phase 1
216
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-04-18
Recruiting
Eli Lilly and Company
Phase 1/2
880
California, Colorado, Connecticut, Florida, Georgia, Iowa, Louisiana, Massachusetts
2023-04-17
Active, closed
Galderma R&D
Not applicable
186
California, Connecticut, Florida, Georgia, Louisiana, Massachusetts, Michigan, New York
2023-04-12
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-04-11
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
California, Connecticut, Florida, Indiana, Louisiana, Michigan, New York, North Carolina
2023-04-04
Recruiting
AstraZeneca
Phase 3
4,300
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2023-03-31
Active, closed
NuvOx LLC
Phase 2
87
Arizona, California, Connecticut, Illinois, Louisiana, Missouri, New Jersey, North Carolina
2023-03-31
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Alaska, Arizona, California, Colorado, Connecticut, Florida, Iowa, Louisiana
2023-03-29
Recruiting
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
GV20 Therapeutics
Phase 1/2
365
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Michigan, New York
2023-03-23
Active, closed
Thoraflex Hybrid and Relay Extension Post-Approval Study
NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm
Vascutek Ltd.
Observational
352
Alabama, California, Colorado, Connecticut, District of Columbia, Illinois, Indiana, Maryland
2023-03-17
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
798
Connecticut, Florida, Iowa, Kentucky, Michigan, Minnesota, New York, Ohio
2023-03-13
By invitation
Eli Lilly and Company
Phase 3
338
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2023-03-09
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-03-09
Active, closed
Pfizer
Phase 3
624
California, Connecticut, Florida, Illinois, Kansas, Kentucky, Louisiana, Mississippi
2023-03-03
Active, closed
The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study
NCT05489588Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
W.L.Gore & Associates
Not applicable
165
California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan, New Jersey
2023-03-02
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-03-02
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2023-03-01
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Day One Biopharmaceuticals, Inc.
Phase 3
418
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-27
Recruiting
Eli Lilly and Company
Phase 3
595
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2023-02-27
Recruiting
Boehringer Ingelheim
Phase 1
66
California, Connecticut, New Jersey, Virginia
2023-02-24
Recruiting
Fore Biotherapeutics
Phase 2
254
California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, Missouri, Nebraska
2023-02-21
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-15
Active, closed
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304Ischemic Stroke, Systemic Embolism
AtriCure, Inc.
Not applicable
6,573
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-01-25
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2023-01-23
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
Abivax S.A.
Phase 3
1,116
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-01-16
Active, closed
Bristol-Myers Squibb
Phase 3
516
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-01-12
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Ellipses Pharma
Phase 1/2
95
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas, Virginia
2023-01-11
Recruiting
Alleviant ALLAY-HF Study
NCT05685303Heart Failure
Alleviant Medical, Inc.
Not applicable
700
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2023-01-10
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical
Not applicable
300
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2023-01-06
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-01-05
Active, closed
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
NCT05653882Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
Asher Biotherapeutics, Inc.
Phase 1
552
California, Connecticut, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2023-01-04
Active, closed
SpermQT Prospective Observational Trial
NCT05966883Male Infertility
Inherent Biosciences
Observational
1,000
California, Colorado, Connecticut, Massachusetts, Texas, Washington
2023-01-01
Active, closed
Ipsen
Phase 2
68
California, Colorado, Connecticut, Florida, Georgia, Louisiana, Maryland, Massachusetts
2022-12-29
Recruiting
Anthos Therapeutics, Inc.
Phase 3
2,500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2022-12-27
Active, closed
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
NCT05446298Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
OncoC4, Inc.
Phase 2
58
Arizona, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana, Minnesota
2022-12-22
Recruiting
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
NCT05313165Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease
LimFlow, Inc.
Not applicable
100
California, Connecticut, Florida, Illinois, Massachusetts, Missouri, New Hampshire, New Jersey
2022-12-22
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
AstraZeneca
Phase 1
190
California, Connecticut, District of Columbia, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2022-12-21
Recruiting
Greenwich LifeSciences, Inc.
Phase 3
2,250
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-12-16
Active, closed
Amgen
Phase 3
7,297
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-12-14
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT05768932Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
SillaJen, Inc.
Phase 1
260
Connecticut, Florida, Georgia, Michigan, New York, Oregon, Texas
2022-12-14
Recruiting
Pharming Technologies B.V.
Phase 2
180
California, Colorado, Connecticut, Florida, Georgia, Indiana, Maryland, Minnesota
2022-12-13
Active, closed
(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds
NCT05364502Arterial Bleeding in Solid Organs and Peripheral Arteries
Instylla, Inc.
Not applicable
130
Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Indiana, Maryland
2022-12-12
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-12-09
Active, closed
Celcuity Inc
Phase 3
701
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2022-12-08
Active, closed
SELUTION4SFA Trial
NCT05132361Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
M.A. Med Alliance S.A.
Not applicable
300
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana
2022-12-01
Active, closed
AstraZeneca
Phase 3
1,174
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2022-11-28
Active, closed
Pfizer
Phase 4
319
California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Louisiana, Massachusetts
2022-11-21
Active, closed
SoniVie Inc.
Not applicable
25
Alabama, Arkansas, Connecticut, Illinois, Minnesota, New York, North Carolina, South Carolina
2022-11-11
Active, closed
Novartis Pharmaceuticals
Phase 2
34
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2022-11-11
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
87
California, Connecticut, Florida, Illinois, Missouri, New York, North Carolina
2022-11-07
Active, closed
Suven Life Sciences Limited
Phase 3
375
California, Connecticut, Florida, Illinois, New Jersey, New York, Ohio, South Carolina
2022-11-01
Active, closed
TScan Therapeutics, Inc.
Phase 1
310
California, Colorado, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan
2022-11-01
Recruiting
Pfizer
Observational
12,500
California, Connecticut, District of Columbia, Georgia, Kentucky, Louisiana, Maryland, Massachusetts
2022-10-27
Active, closed
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05284747Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Amgen
Phase 4
6,019
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2022-10-26
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa
2022-10-25
Active, closed
United Therapeutics
Phase 4
52
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Massachusetts
2022-10-20
Active, closed
Eli Lilly and Company
Phase 3
377
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2022-10-18
Active, closed
Study of Oral MRT-2359 in Selected Cancer Patients
NCT05546268NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL
Monte Rosa Therapeutics, Inc
Phase 1/2
174
Arizona, California, Connecticut, Kansas, Massachusetts, Michigan, Missouri, New York
2022-10-12
Active, closed
Eli Lilly and Company
Phase 3
15,374
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2022-10-11
Active, closed
Eli Lilly and Company
Phase 3
8,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-10-04
Active, closed
PharmaEssentia
Phase 2
91
Alabama, California, Connecticut, District of Columbia, Georgia, Indiana, Kentucky, Louisiana
2022-09-29
Active, closed
AbbVie
Phase 2
125
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Massachusetts
2022-09-28
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
Janssen-Cilag Ltd.
Phase 3
288
Alabama, Connecticut, Florida, Kansas, Kentucky, Missouri, New York, Oklahoma
2022-09-27
Recruiting
Pfizer
Phase 2/3
389
Alabama, Connecticut, Florida, Georgia, Illinois, Louisiana, Michigan, Mississippi
2022-09-22
Recruiting
Celgene
Phase 3
810
California, Colorado, Connecticut, Florida, Georgia, Kansas, Louisiana, Maryland
2022-09-20
Active, closed
Janssen Research & Development, LLC
Phase 2
577
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana
2022-09-19
Recruiting
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Janux Therapeutics
Phase 1
272
Alabama, Arizona, California, Connecticut, Florida, Illinois, Maryland, Minnesota
2022-09-15
Active, closed
Exelixis
Phase 3
901
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2022-09-07
Recruiting
Acrivon Therapeutics
Phase 2
350
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2022-08-29
Recruiting
Alexion Pharmaceuticals, Inc.
Observational
30
Connecticut, Illinois, Massachusetts, Missouri, New York, Ohio, Pennsylvania, Tennessee
2022-08-25
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
410
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, New York
2022-08-23
Active, closed
Adverum Biotechnologies, Inc.
Phase 2
69
Arizona, California, Colorado, Connecticut, Florida, Hawaii, Michigan, Mississippi
2022-08-23
Active, closed
Sanofi
Phase 2/3
1,856
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-08-22
Active, closed
Genmab
Phase 2
184
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-08-17
Recruiting
Bristol-Myers Squibb
Observational
1,700
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-08-16
Active, closed
Gilead Sciences
Phase 2/3
689
California, Colorado, Connecticut, Florida, Georgia, Illinois, Missouri, New Jersey
2022-08-16
Active, closed
CooperVision, Inc.
Not applicable
2,400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Indiana
2022-08-15
Active, closed
Mercator MedSystems, Inc.
Phase 2
60
Connecticut, Florida, Illinois, Louisiana, Maryland, New York, North Carolina, Ohio
2022-08-08
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Panbela Therapeutics, Inc.
Phase 2/3
600
Arkansas, California, Connecticut, District of Columbia, Michigan, Minnesota, New York, Ohio
2022-08-08
Active, closed
Genentech, Inc.
Phase 3
373
Alaska, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2022-08-03
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
43
California, Connecticut, District of Columbia, Illinois, Maryland, Minnesota, New York, Pennsylvania
2022-08-02
Active, closed
Eli Lilly and Company
Phase 4
794
Alabama, California, Connecticut, Florida, Georgia, Indiana, Iowa, Kentucky
2022-08-01
Active, closed
Gilead Sciences
Phase 3
443
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-07-25
Active, closed
PureTech
Phase 2
240
Alabama, California, Connecticut, Florida, Georgia, Indiana, Kansas, North Carolina
2022-07-22
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-07-22
Recruiting
Veracyte, Inc.
Observational
2,400
Connecticut, Florida, Illinois, Kansas, Kentucky, Louisiana, Maryland, Massachusetts
2022-07-18
Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
Dren Bio
Phase 1/2
200
Alabama, California, Connecticut, Florida, Massachusetts, New York, Ohio, Pennsylvania
2022-07-13
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Illinois, Indiana
2022-07-08
Active, closed
Incyte Corporation
Phase 1
291
California, Colorado, Connecticut, Florida, Georgia, New York, North Carolina, Pennsylvania
2022-07-05
Recruiting
Alkermes, Inc.
Phase 3
220
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-06-30
By invitation
Pre-hospital Ventilation Clinical Study
NCT05604430Altered Mental Status, Sepsis, Heart Failure, Hemorrhage
Zoll Medical Corporation
Observational
500
Connecticut, Louisiana, Massachusetts, Texas, Washington
2022-06-30
Active, closed
Celgene
Phase 3
939
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2022-06-23
Active, closed
NanoPharmaceuticals LLC
Phase 1
34
Connecticut
2022-06-23
Recruiting
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114Non-Small Cell Lung Cancer
Tempus AI
Observational
1,200
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2022-06-22
Recruiting
Edwards Lifesciences
Not applicable
1,234
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2022-06-20
Recruiting
Xencor, Inc.
Phase 1
307
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Minnesota
2022-06-13
Active, closed
MOTIV BTK Randomized Controlled Trial
NCT05406622Critical Limb Ischemia
REVA Medical, Inc.
Not applicable
292
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Iowa
2022-06-10
Recruiting
Astellas Pharma Inc
Phase 1
681
California, Colorado, Connecticut, District of Columbia, Florida, Kansas, Massachusetts, Michigan
2022-06-08
Active, closed
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
NCT05428969Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
Faron Pharmaceuticals Ltd
Phase 1/2
181
California, Connecticut, North Carolina, Texas
2022-06-02
Active, closed
ModernaTX, Inc.
Phase 1/2
15
Connecticut, Massachusetts, North Carolina, Ohio, Pennsylvania, Texas, Utah
2022-06-01
Active, closed
HEAL-IST IDE Trial
NCT05280093Inappropriate Sinus Tachycardia
AtriCure, Inc.
Not applicable
100
Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Kansas
2022-05-31
Recruiting
Bristol-Myers Squibb
Phase 2/3
120
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2022-05-30
Active, closed
Artivion Inc.
Not applicable
115
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts
2022-05-27
Recruiting
SELUTION4BTK Trial
NCT05055297Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
M.A. Med Alliance S.A.
Not applicable
376
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2022-05-19
Active, closed
Shanghai Henlius Biotech
Phase 3
511
California, Colorado, Connecticut, Florida, Kansas, Louisiana, Minnesota, Nevada
2022-05-17
Active, closed
AstraZeneca
Phase 3
644
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Kentucky, Michigan
2022-05-16
By invitation
Posterior Cervical Fixation Study
NCT04770571Degenerative Disc Disease, Craniocervical Injuries, Cervical Radiculopathy, Cervical Disc Disease
NuVasive
Observational
150
California, Connecticut, Maryland, New York, Pennsylvania, Tennessee, Texas
2022-05-10
Active, closed
RADIANCE Continued Access Protocol
NCT05017935Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
ReCor Medical, Inc.
Not applicable
300
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Louisiana
2022-05-04
Active, closed
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755Moderate Aortic Valve Stenosis
Medtronic Cardiovascular
Not applicable
650
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Kentucky
2022-04-27
Active, closed
US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT05232838Hydrocephalus, Normal Pressure, Hydrocephalus
CereVasc Inc
Not applicable
50
Connecticut, Florida, Kansas, Kentucky, Massachusetts, New York, Rhode Island, Virginia
2022-04-20
Active, closed
Sanofi
Phase 3
43
Connecticut, Iowa, Texas, Virginia
2022-04-18
Recruiting
AstraZeneca
Phase 2
630
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-04-14
Active, closed
CONVERGE Post-Approval Study (PAS)
NCT05393180Chronic Atrial Fibrillation
AtriCure, Inc.
Not applicable
53
California, Connecticut, Florida, Georgia, Kentucky, Maryland, Massachusetts, New Jersey
2022-04-13
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
Nurix Therapeutics, Inc.
Phase 1
572
California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland, New York
2022-04-13
Recruiting
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
NCT05406167Cancer, Cancer Central Nervous System, Cancer Thoracic, Cancer, Gastrointestinal
RefleXion Medical
Observational
500
California, Connecticut, Pennsylvania, Texas
2022-04-12
Active, closed
Protagonist Therapeutics, Inc.
Phase 3
293
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2022-04-11
Recruiting
Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry
NCT04829175Stress Urinary Incontinence, Pelvic Organ Prolapse
Ethicon, Inc.
Observational
1,000
Connecticut, North Carolina, Pennsylvania
2022-04-11
Active, closed
Delfi Diagnostics Inc.
Observational
11,935
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2022-04-07
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 2/3
522
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2022-03-30
Active, closed
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
154
Arizona, California, Colorado, Connecticut, District of Columbia, Maryland, Massachusetts, Michigan
2022-03-29
Active, closed
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT05477576GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
RayzeBio, Inc.
Phase 3
343
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Iowa, Kentucky
2022-03-24
Recruiting
OssDsign® Spine Registry Study ("Propel")
NCT05329129Degenerative Disc Disease, Spinal Stenosis
OssDsign
Observational
450
California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2022-03-23
Recruiting
ORIC Pharmaceuticals
Phase 1/2
350
California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2022-03-10
Active, closed
Janssen Research & Development, LLC
Phase 2
151
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York, North Carolina
2022-03-01
Active, closed
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809Osteogenesis Imperfecta
Ultragenyx Pharmaceutical Inc
Phase 2/3
183
Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois
2022-02-21
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 2
310
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2022-02-17
Active, closed
Seattle Project Corporation
Phase 2/3
700
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Indiana
2022-02-12
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2/3
286
California, Connecticut, District of Columbia, Florida, Illinois, Indiana, Louisiana, Maryland
2022-02-11
Active, closed
AstraZeneca
Phase 3
1,051
California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan
2022-02-07
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2022-02-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2022-02-03
Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
Impulse Dynamics
Not applicable
1,500
Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Iowa
2022-02-03
Active, closed
Tumor-induced Osteomalacia Disease Monitoring Program
NCT04783428Tumor-induced Osteomalacia (TIO)
Ultragenyx Pharmaceutical Inc
Observational
23
Connecticut, Indiana, Maryland, Tennessee, Virginia
2022-01-31
Recruiting
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
Synthekine
Phase 1/2
364
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland
2022-01-25
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-01-19
By invitation
AbbVie
Phase 3
1,200
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-01-14
Recruiting
AbbVie
Phase 3
1,059
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-01-13
Active, closed
Guardant Health, Inc.
Observational
12,000
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2022-01-13
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
AbbVie
Phase 3
735
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2022-01-13
Recruiting
Shockwave Medical, Inc.
Not applicable
380
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2022-01-04
Active, closed
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Ono Pharmaceutical Co., Ltd.
Phase 2
119
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2021-12-29
Active, closed
INSPIRE Pipeline™ Shield Post Approval Study
NCT05071963Intracranial Aneurysm
Medtronic Neurovascular Clinical Affairs
Observational
246
Alabama, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri, New York
2021-12-20
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
Exelixis
Phase 1
1,394
Arizona, California, Colorado, Connecticut, Delaware, Florida, Illinois, Indiana
2021-12-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2021-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana, Kansas
2021-12-13
Active, closed
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
NCT05079282Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co., Ltd.
Phase 1
217
Alabama, California, Connecticut, Georgia, Massachusetts, Michigan, Missouri, New Jersey
2021-12-10
Recruiting
Relay Therapeutics, Inc.
Phase 1
930
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Massachusetts
2021-12-08
Recruiting
UCB Biopharma SRL
Phase 3
350
Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Hawaii, Idaho
2021-12-07
Recruiting
H. Lundbeck A/S
Phase 3
600
Connecticut, Florida, Kentucky, Maryland, Michigan, New York, North Carolina, Ohio
2021-12-01
Rows per page Showing 501–1000 of 1301
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 November 2026. https://priyalifescience.com/clinical-trials-usa/state/connecticut?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 22 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,301 of those studies with a site in Connecticut.

How many clinical trials are recruiting in Connecticut?

670 of the 1,301 studies on this page are recruiting new participants as of the 22 Nov 2026, 03:16 UTC sync. A further 22 have not yet opened recruitment, 576 are active but closed to new participants, and 33 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.